Showing results (1-10 of 33) with videos related to
Sort By:
Pageof 4
Bulletin Du Cancer|August 3, 2023
[Myelodysplastic syndrome : prognostic factors]Emmanuel Gyan, Sylvain ThépotDrug Discovery Today|June 6, 2018
Advances in treatment formulations for acute myeloid leukemiaThomas Briot, Emilie Roger, Sylvain Thépot, et al.Ejhaem|September 2, 2022
Progressive multifocal leukoencephalopathy after durvalumab treatment for acute myeloid leukemia: A consequence of an immune reconstitution inflammatory syndrome?Emeline Vinatier, Caroline Poli, Aurélien Giltat, et al.International Journal of Nanomedicine|April 17, 2019
Di-O-lauroyl-decitabine-lipid nanocapsules: toward extending decitabine activityThomas Briot, Emilie Roger, Naila Bou Haidar, et al.Cell Cycle (Georgetown, Tex.)|October 26, 2012
Erlotinib antagonizes ABC transporters in acute myeloid leukemiaElodie Lainey, Marie Sébert, Sylvain Thépot, et al.Bulletin Du Cancer|July 16, 2019
[Renal failure after allogeneic hematopoietic stem cell transplantation: Recommendations of the Francophone Society of Bone Marrow transplantation and cellular Therapy (SFGM-TC)]Marie Detrait, Eva de Berranger, Remy Dulery, et al.Bulletin Du Cancer|April 7, 2019
[Hepatobiliary complications following allogeneic hematopoietic cell transplantation: Recommendations of the Francophone Society of Bone Marrow transplantation and cellular Therapy (SFGM-TC)]Marie Detrait, Eva de Berranger, Remy Dulery, et al.Biochemical Pharmacology|June 14, 2011
Tyrosine kinase inhibitors for the treatment of acute myeloid leukemia: delineation of anti-leukemic mechanisms of actionElodie Lainey, Sylvain Thépot, Cyrielle Bouteloup, et al.Leukemia Research|March 5, 2015
Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failureStéphanie Harel, Amina Cherait, Céline Berthon, et al.Journal of Clinical Immunology|April 16, 2010
Immunoglobulin dosage and switch from intravenous to subcutaneous immunoglobulin replacement therapy in patients with primary hypogammaglobulinemia: decreasing dosage does not alter serum IgG levelsSylvain Thépot, Marion Malphettes, Anaëlle Gardeur, et al.Pageof 4